MAPT and Alzheimer disease: While AD-specific biomarkers correlate with amyloid and tau deposition (Chong et al., 2021), these may not necessarily reflect consequential pathology in all cases and so may be relatively elevated in individuals with unrecognised asymptomatic AD within the healthy comparator group, reducing the specificity in differentiating MCI from healthy controls.